Form 4: KalVista CMO Executes RSU Vesting and Tax Sale

Chief Medical Officer Paul K. Audhya acquired 6,250 shares via RSU vesting and sold 2,686 shares to cover tax obligations.

Summary

• Paul K. Audhya, Chief Medical Officer of KalVista Pharmaceuticals, Inc., reported the vesting of 6,250 restricted stock units (RSUs) on April 16, 2026.
• Following the vesting, 2,686 shares were sold on April 17, 2026, at an average price of $20.2163 per share.
• The sale was executed specifically to satisfy mandatory tax withholding obligations related to the RSU settlement.
• The reporting person retains 142,547 shares of common stock following these transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is a routine administrative action related to tax obligations rather than a discretionary market move.

Positives

• The transaction reflects the ongoing vesting of equity compensation, aligning the interests of the Chief Medical Officer with long-term shareholder value.

Negatives

• The sale of shares, while for tax purposes, reduces the direct equity stake held by the executive.

Risks

• Continued service requirements for the remaining 93,750 unvested RSUs could impact future compensation if the executive departs.

Future Outlook

The remaining 93,750 RSUs are subject to quarterly vesting over time, contingent upon the reporting person's continued service to the company.

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are standard practice in the biotechnology sector, where executives frequently receive equity-based compensation that triggers immediate tax liabilities upon vesting.

Comparison to Industry Standards

• The transaction structure is consistent with standard executive compensation practices in the pharmaceutical industry.
• The use of 'sell-to-cover' is a common, non-discretionary mechanism used by executives at peers like Alnylam or Ionis to manage tax obligations.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was non-discretionary and limited to tax coverage.

Next Steps

• Continued quarterly vesting of the remaining 93,750 RSUs.

Key Dates

Keywords

KalVista Pharmaceuticals, KALV, Insider Trading, Form 4, Equity Compensation, Chief Medical Officer